SART-3 Inhibitors
Chemical inhibitors of SART3 can disrupt its function in RNA splicing by targeting various kinases that play a role in cell cycle regulation and RNA processing. Alsterpaullone, for instance, is known to inhibit cyclin-dependent kinases (CDKs), which are crucial for the regulation of the cell cycle. Since CDKs can also regulate RNA processing factors, the inhibition by alsterpaullone can lead to a reduction in SART3 activity in RNA splicing. Similarly, roscovitine and flavopiridol, both potent CDK inhibitors, can interfere with the transcriptional regulators and RNA polymerase II, further inhibiting the splicing function of SART3. Indirubin-3'-monoxime and olomoucine, which also target CDKs, can affect the phosphorylation state of proteins involved in RNA processing, thereby hindering SART3's role in spliceosome assembly.
In parallel, bisindolylmaleimide I and Ro-31-8220 inhibit protein kinase C (PKC), which is implicated in signaling pathways that regulate RNA processing. The inhibition of PKC by these chemicals disrupts these pathways and can diminish SART3's activity in RNA splicing. H-7, which inhibits not only PKC but also other kinases such as PKA and PKG, can lead to similar outcomes. Other chemical inhibitors such as SP600125, which targets the c-Jun N-terminal kinase (JNK), can indirectly affect RNA splicing factors and thus impede SART3's function. Additionally, 5-Iodotubercidin inhibits adenosine kinase, which may influence RNA processing enzymes due to changes in cellular adenosine levels, subsequently affecting SART3's role in spliceosome assembly. Lastly, K252a, while primarily studied in the context of neurotrophin receptors, can influence broader kinase pathways and thereby have an impact on RNA splicing, affecting SART3's function. Each of these inhibitors, through their respective targets, can contribute to the reduction of SART3's activity in the RNA splicing process.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are integral for cell cycle regulation. As SART3 is involved in spliceosome assembly and function, and CDKs can regulate RNA processing factors, alsterpaullone inhibition of CDKs can hinder SART3's role in RNA splicing. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I functions as a protein kinase C (PKC) inhibitor. PKC has roles in various signaling pathways, including those that regulate RNA processing. Inhibition of PKC can disrupt these pathways, possibly reducing SART3's activity in RNA splicing. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK participates in signaling pathways that can affect RNA splicing factors. By inhibiting JNK, SP600125 may indirectly impair SART3's function in spliceosome assembly and RNA splicing activities. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
Ro-31-8220 is a potent PKC inhibitor which can also affect related kinases. Since PKC influences numerous cellular processes including those related to RNA processing, Ro-31-8220 inhibition of PKC can lead to a decrease in SART3's involvement in RNA splicing. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad spectrum kinase inhibitor that can inhibit a range of kinases involved in cell cycle control and RNA processing. Its broad action can interfere with kinases that regulate SART3's activity, thereby inhibiting SART3's function in RNA splicing. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
5-Iodotubercidin inhibits adenosine kinase, which can influence cellular adenosine levels and subsequently affect RNA processing enzymes. Through this mechanism, 5-Iodotubercidin can indirectly inhibit SART3's function in spliceosome assembly and RNA splicing. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs which are known to regulate transcription and post-transcriptional mechanisms including RNA splicing. Inhibition of CDKs by roscovitine can indirectly lead to functional inhibition of SART3's role in splicing. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is a CDK inhibitor which can impair cell cycle progression and related RNA processing events. By inhibiting CDKs, the chemical can indirectly inhibit SART3's activity in spliceosome assembly and function. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a potent CDK inhibitor that has been shown to have effects on transcriptional regulators and RNA polymerase II. By inhibiting these processes, flavopiridol can indirectly inhibit SART3's function in RNA splicing. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor that can affect the phosphorylation state of proteins involved in RNA processing. By doing so, olomoucine can indirectly inhibit the function of SART3 in spliceosome assembly and RNA splicing. | ||||||